Want to see HK:6681 full AI Analyst Report?
BrainAurora Medical Technology Limited (6681) Ratios
BrainAurora Medical Technology Limited Ratios
HK:6681's free cash flow for Q2 2026 was $0.00. For the 2026 fiscal year, HK:6681's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.56 | 0.70 | 0.77 | 8.62 | 1.93 |
| Quick Ratio | 1.56 | 0.70 | 0.77 | 8.62 | 1.93 |
| Cash Ratio | 0.77 | 0.44 | 0.15 | 1.64 | 1.83 |
| Solvency Ratio | -0.45 | -0.16 | -0.46 | -0.32 | -0.66 |
| Operating Cash Flow Ratio | -0.42 | -0.19 | -0.35 | -2.83 | -0.28 |
| Short-Term Operating Cash Flow Coverage | -0.51 | -1.56 | -6.20 | -14.46 | 0.00 |
| Net Current Asset Value | $ 24.05M | $ -515.39M | $ -424.31M | $ -1.21B | $ -711.88M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.77 | 0.65 | 0.92 | 0.78 | 0.83 |
| Debt-to-Equity Ratio | 5.81 | -0.84 | -1.10 | -0.30 | -0.45 |
| Debt-to-Capital Ratio | 0.85 | -5.15 | 11.40 | -0.43 | -0.83 |
| Long-Term Debt-to-Capital Ratio | 0.68 | -1.41 | -122.01 | -0.40 | -0.75 |
| Financial Leverage Ratio | 7.53 | -1.29 | -1.19 | -0.38 | -0.54 |
| Debt Service Coverage Ratio | -0.72 | -1.50 | -7.51 | -17.98 | -107.94 |
| Interest Coverage Ratio | -12.13 | -7.82 | -7.22 | -5.43 | -10.82 |
| Debt to Market Cap | 0.08 | 0.13 | 0.13 | 0.09 | 0.08 |
| Interest Debt Per Share | 0.51 | 0.45 | 0.43 | 0.27 | 0.25 |
| Net Debt to EBITDA | -0.90 | -0.25 | -0.96 | -0.57 | 0.02 |
| Profitability Margins | |||||
| Gross Profit Margin | 40.65% | 44.16% | 47.71% | 29.20% | 56.72% |
| EBIT Margin | -132.22% | -144.33% | -504.32% | -4279.85% | -30075.99% |
| EBITDA Margin | -120.33% | -144.33% | -472.67% | -4169.76% | -30005.18% |
| Operating Profit Margin | -132.22% | -140.85% | -217.16% | -923.88% | -3007.61% |
| Pretax Profit Margin | -143.72% | -162.34% | -534.40% | -4450.10% | -30353.98% |
| Net Profit Margin | -143.09% | -162.11% | -534.35% | -4450.02% | -30353.94% |
| Continuous Operations Profit Margin | -143.77% | -162.38% | -534.40% | -4450.10% | -30353.98% |
| Net Income Per EBT | 99.56% | 99.86% | 99.99% | 100.00% | 100.00% |
| EBT Per EBIT | 108.70% | 115.26% | 246.08% | 481.68% | 1009.24% |
| Return on Assets (ROA) | -42.94% | -33.07% | -90.94% | -120.18% | -187.95% |
| Return on Equity (ROE) | -323.31% | 42.77% | 108.11% | 45.92% | 102.43% |
| Return on Capital Employed (ROCE) | -94.14% | 94.39% | -7260.35% | -27.27% | -35.58% |
| Return on Invested Capital (ROIC) | -43.90% | 230.42% | -455.76% | -26.28% | -34.39% |
| Return on Tangible Assets | -43.70% | -33.24% | -91.92% | -120.34% | -187.98% |
| Earnings Yield | -4.67% | -7.01% | -13.16% | -13.49% | -20.32% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.69 | 0.91 | 0.88 | 0.57 | 0.14 |
| Payables Turnover | 6.96 | 19.98 | 4.26 | 4.54 | 6.26 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 4.86 | 2.75 | 1.83 | 0.33 | 0.08 |
| Asset Turnover | 0.30 | 0.20 | 0.17 | 0.03 | 0.01 |
| Working Capital Turnover Ratio | 117.59 | -0.76 | 0.74 | 0.05 | 0.00 |
| Cash Conversion Cycle | 163.12 | 382.27 | 327.37 | 556.53 | 2561.77 |
| Days of Sales Outstanding | 215.57 | 400.54 | 413.09 | 636.93 | 2620.09 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 52.45 | 18.27 | 85.71 | 80.41 | 58.33 |
| Operating Cycle | 215.57 | 400.54 | 413.09 | 636.93 | 2620.09 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.15 | -0.17 | -0.15 | -0.08 | -0.04 |
| Free Cash Flow Per Share | -0.18 | -0.18 | -0.17 | -0.09 | -0.05 |
| Dividend Paid and CapEx Coverage Ratio | -6.42 | -8.42 | -7.55 | -5.28 | -4.43 |
| Capital Expenditure Coverage Ratio | -6.42 | -8.42 | -7.55 | -5.28 | -4.43 |
| Operating Cash Flow Coverage Ratio | -0.31 | -0.38 | -0.38 | -0.31 | -0.16 |
| Operating Cash Flow to Sales Ratio | -0.81 | -1.22 | -2.04 | -8.92 | -21.40 |
| Free Cash Flow Yield | -3.05% | -5.91% | -5.68% | -3.22% | -1.76% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -21.42 | -14.26 | -7.60 | -7.41 | -4.92 |
| Price-to-Sales (P/S) Ratio | 30.65 | 23.12 | 40.60 | 329.76 | 1493.73 |
| Price-to-Book (P/B) Ratio | 69.27 | -6.10 | -8.21 | -3.40 | -5.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -32.79 | -16.91 | -17.60 | -31.10 | -56.94 |
| Price-to-Operating Cash Flow Ratio | -37.89 | -18.92 | -19.93 | -36.98 | -69.79 |
| Price-to-Earnings Growth (PEG) Ratio | -0.94 | 0.32 | 0.00 | 0.27 | 0.00 |
| Enterprise Value Multiple | -26.38 | -16.27 | -9.55 | -8.48 | -4.96 |
| Enterprise Value | 6.98B | 2.87B | 3.03B | 3.99B | 3.42B |
| EV to EBITDA | -26.38 | -16.27 | -9.55 | -8.48 | -4.96 |
| EV to Sales | 31.74 | 23.48 | 45.16 | 353.65 | 1487.22 |
| EV to Free Cash Flow | -33.95 | -17.17 | -19.58 | -33.35 | -56.69 |
| EV to Operating Cash Flow | -39.23 | -19.21 | -22.17 | -39.66 | -69.49 |
| Tangible Book Value Per Share | 0.07 | -0.52 | -0.37 | -0.86 | -0.54 |
| Shareholders’ Equity Per Share | 0.08 | -0.51 | -0.37 | -0.86 | -0.54 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.19 | 0.14 | 0.07 | 0.01 | 0.00 |
| Net Income Per Share | -0.27 | -0.22 | -0.40 | -0.40 | -0.55 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.09 | 1.12 | 1.06 | 1.04 | 1.01 |
| Research & Development to Revenue | 0.75 | 0.98 | 1.35 | 5.99 | 14.25 |
| SG&A to Revenue | 0.80 | 0.88 | 0.16 | 0.85 | 4.36 |
| Stock-Based Compensation to Revenue | 0.35 | 0.00 | 0.67 | 0.00 | 8.43 |
| Income Quality | 0.56 | 0.74 | 0.38 | 0.20 | 0.07 |
Currency in CNY